- Home
- UPST vs BEAM Comparison
UPST vs BEAM Comparison
Compare UPST & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | BEAM |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | UPST | BEAM |
|---|---|---|
| Price | $26.82 | $25.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | $45.84 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 3.6M | 2.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,043,857,000.00 | $24,000.00 |
| Revenue This Year | $34.45 | N/A |
| Revenue Next Year | $32.64 | $33.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 63.99 | 33.33 |
| 52 Week Low | $23.97 | $15.60 |
| 52 Week High | $85.31 | $38.26 |
Technical Indicators
Market Signals| Indicator | UPST | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 30.23 |
| Support Level | $25.18 | $24.80 |
| Resistance Level | $34.84 | $33.32 |
| Average True Range (ATR) | 1.62 | 1.99 |
| MACD | -0.65 | -0.94 |
| Stochastic Oscillator | 1.37 | 1.83 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.